DOI:
10.1055/s-00034914
Osteologie
LinksClose Window
References
Langdahl BL, Libanati C, Crittenden DB. et al.
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
Lancet 2017;
390: 1585-1594.
DOI: 10.1016/S0140-6736(17)31613-6.
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.